A Safety Study of Pentoxifylline for the Treatment of Anemia
Recruiting in Palo Alto (17 mi)
+9 other locations
RM
Overseen byRaymond M. Hakim, MD, PhD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Fresenius Medical Care North America
No Placebo Group
Prior Safety Data
Approved in 3 Jurisdictions
Trial Summary
What is the purpose of this trial?
Chronic kidney disease (CKD) patients have increased levels of inflammation and oxidative stress, which in turn contribute to anemia and cardiovascular disease. Pentoxifylline is known to have anti-inflammatory and anti-oxidant properties, and has shown promise in improving the treatment of patients with anemia. This study will examine the use of pentoxifylline for the treatment of anemia in chronic kidney disease.
Research Team
RM
Raymond M. Hakim, MD, PhD
Principal Investigator
Fresenius Medical Care North America
Eligibility Criteria
Inclusion Criteria
Male or female, aged ≥18 years;
Able to comply with the study procedures and medication;
Written informed consent given;
See 7 more
Treatment Details
Interventions
- Erythropoietin (Other)
- Pentoxifylline (Other)
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: erythropoietin plus pentoxifyllineExperimental Treatment2 Interventions
Group II: erythropoietin aloneActive Control1 Intervention
Pentoxifylline is already approved in Canada for the following indications:
Approved in Canada as Trental for:
- Intermittent claudication
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Fresenius Medical Care North AmericaColumbia, TN
Fresenius Medical Care North AmericaIrving, TX
Fresenius Medical Care North AmericaTyler, TX
Fresenius Medical Care North AmericaSt. Ann, MO
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Fresenius Medical Care North America
Lead Sponsor
Trials
40
Patients Recruited
78,400+